Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.46 |
| ▸ | STAT6 | P42226 | 5/20 | 0.42 |
| ▸ | JAK2 | O60674 | 9/20 | 0.42 |
| ▸ | BRD4 | O60885 | 9/20 | 0.42 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1655070 | 0.95 | RPS6KA3 (0.44) | RPS6KA3STAT6JAK2BRD4AURKA | |
| SCHEMBL1657602 | 0.91 | JAK2 (0.44) | RPS6KA3STAT6JAK2BRD4AURKA | |
| SCHEMBL1655183 | 0.91 | RPS6KA3 (0.49) | RPS6KA3STAT6JAK2BRD4AURKA | |
| SCHEMBL1655037 | 0.90 | RPS6KA3 (0.46) | RPS6KA3STAT6JAK2BRD4AURKA | |
| SCHEMBL1655035 | 0.90 | RPS6KA3 (0.46) | RPS6KA3STAT6JAK2BRD4AURKA | |
| SCHEMBL3402199 | 0.89 | RPS6KA3 (0.50) | RPS6KA3STAT6JAK2BRD4AURKA | |
| SCHEMBL1654764 | 0.88 | RPS6KA3 (0.48) | RPS6KA3STAT6JAK2BRD4 | |
| SCHEMBL1654504 | 0.88 | RPS6KA3 (0.47) | RPS6KA3STAT6JAK2BRD4 | |
| SCHEMBL4291665 | 0.88 | RPS6KA3 (0.46) | RPS6KA3STAT6JAK2BRD4AURKA | |
| SCHEMBL1655275 | 0.87 | RPS6KA3 (0.47) | RPS6KA3STAT6JAK2BRD4AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | claimed |
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| WO-2009098236-A1 | PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | RPS6KA3 303/4885STAT6 601/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.